This inventor holds 8 USPTO granted patents and 2 EPO patents. Top assignee: Applied Biosystems, LLC. Active years: 2012-2021.
Location History:
- Austin, TX (US) (2012 - 2016)
- Mountain House, CA (US) (2017 - 2021)
Company Filing History:
Years Active: 2012-2021
Title: The Innovative Contributions of Irudaya Charles
Introduction
Irudaya Charles is a prominent inventor based in Austin, TX, known for his significant contributions to the field of RNA interference (RNAi). With a total of 8 patents to his name, he has made remarkable advancements in reducing off-target effects in RNAi applications. His work is pivotal in enhancing the efficacy and safety of RNA-based therapeutics.
Latest Patents
Irudaya Charles's latest patents focus on siRNA sequence-independent modification formats aimed at reducing off-target phenotypic effects in RNAi. These innovative modification formats incorporate modified nucleotides that enhance the stability of short interfering RNA (siRNA) in nuclease-rich environments. His research demonstrates that while maintaining strand bias is essential for potency in endogenous RNA interference, it is not solely sufficient for minimizing off-target effects in cell biology assays. This groundbreaking work is crucial for the development of more effective RNAi therapies.
Career Highlights
Irudaya Charles is currently employed at Applied Biosystems, LLC, where he continues to push the boundaries of RNA research. His expertise in the field has led to significant advancements that are shaping the future of genetic research and therapeutic applications. His innovative approaches have garnered attention and respect within the scientific community.
Collaborations
Irudaya collaborates with esteemed colleagues such as Nitin Puri and Alexander Vlassov, contributing to a dynamic research environment that fosters innovation and discovery. Their combined expertise enhances the potential for groundbreaking advancements in RNAi technology.
Conclusion
Irudaya Charles's contributions to the field of RNA interference are invaluable, as he continues to innovate and improve the safety and efficacy of RNA-based therapies. His work exemplifies the impact of dedicated research and collaboration in advancing scientific knowledge.